In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183

Randy S. Schrecengost(Apogee Biotechnology (United States)), Charles D. Smith(Pennsylvania State University)
Journal of Pharmacology and Experimental Therapeutics
February 6, 2018
10.1124/jpet.117.245738
Cited by 16

Related Papers

Pharmacology and Antitumor Activity of ABC294640, a Selective Inhibitor of Sphingosine Kinase-2
|Journal of Pharmacology and Experimental Therapeutics|2010|313
A Novel Sphingosine Kinase Inhibitor Induces Autophagy in Tumor Cells
|Journal of Pharmacology and Experimental Therapeutics|2010|111
Characterization of Isoenzyme-Selective Inhibitors of Human Sphingosine Kinases
|PLoS ONE|2012|107
Recent Progress in the Development of Opaganib for the Treatment of Covid-19
|Drug Design Development and Therapy|2022|27
Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy
|International Journal of Molecular Sciences|2023|18